Natera Fights Illumina's Bid To Invalidate DNA Testing Patent
Natera Inc. pushed back Wednesday against Illumina Inc.'s assertions that Natera's patent covering fetal DNA testing technology for detecting Down syndrome was invalid in light of the prior art, contending that...To view the full article, register now.
Already a subscriber? Click here to view full article